<DOC>
	<DOCNO>NCT01199965</DOCNO>
	<brief_summary>Compare pharmacokinetics Dihydroergotamine Mesylate ( DHE ) deliver oral inhalation ( MAP0004 ) Intravenous ( IV ) DHE smoker versus non-smokers . Identify whether clinically significant difference tolerability MAP0004 smokers non-smokers .</brief_summary>
	<brief_title>Pharmacokinetics &amp; Tolerability Study MAP0004 Smoking Non-Smoking Adult Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Dihydroergotamine</mesh_term>
	<criteria>Major 1 . Able provide write informed consent 2 . Male Female subject 18 45 year old 3 . Female subject practice adequate contraception sterile 4 . Stable cardiac status 5 . Normal rhythm arrhythmia deem clinically insignificant ECG Major 1 . Contraindication dihydroergotamine mesylate ( DHE ) 2 . Use excluded concomitant medication within 10 day prior Visit 1 ( See Section 5.5 ) 3 . History hemiplegic basilar migraine 4 . Participation another investigational trial 30 day prior Visit 1 trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>